Skip to main content

Advertisement

SpringerLink
Log in

Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Combined targeting with a PI3-kinase inhibitor, BKM120, and an Hsp90 inhibitor, HSP990, was investigated as a multi-targeted approach to potentiate cell death in glioblastoma (GBM). Additionally, the effect of dual drug treatment combined with cytotoxic stress (radiation therapy) was examined.

Methods

Four human GBM cell lines containing wild-type or mutated PTEN and/or p53 were studied. The effects of drug treatments on cell viability, apoptosis induction, pAKt activity, cell cycle arrest, clonogenicity, and tumor growth delay were studied.

Results

Combined concurrent treatment with both drugs produced more cell killing in cell viability and apoptosis assays than either drug alone. BKM120 plus HSP990 induced suppression of baseline Akt signaling as well as radiation (RT)-induced pAkt signaling in all cell lines. Cell cycle analysis revealed that HSP990 and BKM120, singly or combined, induced G2/M arrest leading to apoptosis/necrosis and polyploidy. Additionally, the drugs radiosensitized GBM cells in clonogenic assays. In vivo tumor growth delay studies demonstrated the effectiveness of combined drug treatment with HSP990 and BKM120 over single drug treatment, as well as the effectiveness of combined drug treatment in enhancing the effectiveness of radiation therapy.

Conclusions

In conclusion, HSP990 and BKM120, with and without RT, are active agents against glioma tumors. The sensitivity to these agents does not appear to depend on PTEN/p53status in the cell lines tested. We suggest that the combined action of both drugs is a viable multi-targeted strategy with the potential to improve clinical outcome for patients with high-grade glioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Beal K, Abrey LE, Gutin PH (2011) Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 6:2

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Camphausen K, Tofilon PJ (2007) Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin Cancer Res 13:4326–4330

    Article  CAS  PubMed  Google Scholar 

  • Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, Loeffler JS (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22:1926–1933

    Article  CAS  PubMed  Google Scholar 

  • Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8

    Google Scholar 

  • Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231–241

    Article  CAS  PubMed  Google Scholar 

  • Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y, Gajula RP, Williams RD, Cades JA, Annadanam A, Song D, Zhang Y, Hales RK, Herman JM, Armour E, Deweese TL, Schaeffer EM, Tran PT (2013) Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biol Ther 14:347–356

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Garcia-Carbonero R, Carnero A, Paz-Ares L (2013) Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 14:e358–e369

    Article  CAS  PubMed  Google Scholar 

  • Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, Pearson A, Vassal G, Workman P (2010) Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 9:1219–1233

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Hartmann S, Gunther N, Biehl M, Katzer A, Kuger S, Worschech E, Sukhorukov VL, Krohne G, Zimmermann H, Flentje M, Djuzenova CS (2013) Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines. Cancer Lett 331:200–210

    Article  CAS  PubMed  Google Scholar 

  • Jackrel ME, Shorter J (2011) Shock and awe: unleashing the heat shock response to treat Huntington disease. J Clin Invest 121:2972–2975

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK (2012) Antitumor activity of NVP-BKM120–a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18:184–195

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Lang SA, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt HJ, Geissler EK, Stoeltzing O (2009) Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 49:523–532

    Article  CAS  PubMed  Google Scholar 

  • Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chene P, Shoemaker K, De PA, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, Garcia-Echeverria C, Sellers WR, Voliva CF (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11:317–328

    Article  CAS  PubMed  Google Scholar 

  • Niewidok N, Wack LJ, Schiessl S, Stingl L, Katzer A, Polat B, Sukhorukov VL, Flentje M, Djuzenova CS (2012) Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 may exert a significant radiosensitization on tumor cells along with a cell type-specific cytotoxicity. Transl Oncol 5:356–369

    Article  PubMed Central  PubMed  Google Scholar 

  • Premkumar DR, Arnold B, Jane EP, Pollack IF (2006) Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells. Mol Carcinog 45:47–59

    Article  CAS  PubMed  Google Scholar 

  • Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, O’Neill P, McKenna WG, Patel S, Bernhard EJ (2008) Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 68:5915–5923

    Article  CAS  PubMed  Google Scholar 

  • Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96:219–230

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Redlak MJ, Miller TA (2011) Targeting PI3 K/Akt/HSP90 signaling sensitizes gastric cancer cells to deoxycholate-induced apoptosis. Dig Dis Sci 56:323–329

    Article  CAS  PubMed  Google Scholar 

  • Roforth MM, Tan C (2008) Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells. Anticancer Drugs 19:681–688

    Article  CAS  PubMed  Google Scholar 

  • Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101

    Article  CAS  PubMed  Google Scholar 

  • Shtivelman E, Sussman J, Stokoe D (2002) A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol 12:919–924

    Article  CAS  PubMed  Google Scholar 

  • Sinclair WK, Morton RA (1965) X-ray and ultraviolet sensitivity of synchronized Chinese hamster cells at various states of the cell cycle. Biophys J 5:1–25

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127–4136

    Article  CAS  PubMed  Google Scholar 

  • Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466

    Article  CAS  PubMed  Google Scholar 

  • Taipale M, Jarosz DF, Lindquist S (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11:515–528

    Article  CAS  PubMed  Google Scholar 

  • Wachsberger PR, Lawrence YR, Liu Y, Daroczi B, Xu X, Dicker AP (2012) Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts. Int J Radiat Oncol Biol Phys 82(1):483–491

    Article  CAS  PubMed  Google Scholar 

  • Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66:7864–7869

    Article  CAS  PubMed  Google Scholar 

  • Wen PY, Lee EQ, Reardon DA, Ligon KL, fred Yung WK (2012) Current clinical development of PI3 K pathway inhibitors in glioblastoma. Neuro Oncol 14:819–829

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Zaidi S, McLaughlin M, Bhide SA, Eccles SA, Workman P, Nutting CM, Huddart RA, Harrington KJ (2012) The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS ONE 7:e35436

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by an unrestricted grant from Novartis Pharmaceuticals (to PRW and APD).

Conflict of interest

The authors state that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Thomas Jefferson University, Jefferson Alumni Hall, Room 341, 1020 Locust St., Philadelphia, PA, 19107, USA

    Phyllis R. Wachsberger, Yi Liu, Barbara Rice, Nicholas Feo, Benjamin Leiby & Adam P. Dicker

  2. Department of Radiation Oncology, Sheba Medical Center, Ramat Gan, Israel

    Yaacov Richard Lawrence

Authors
  1. Phyllis R. Wachsberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yaacov Richard Lawrence
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barbara Rice
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicholas Feo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Benjamin Leiby
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Adam P. Dicker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Phyllis R. Wachsberger.

Additional information

Phyllis R. Wachsberger and Yaacov Richard Lawrence are joint first authors.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wachsberger, P.R., Lawrence, Y.R., Liu, Y. et al. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J Cancer Res Clin Oncol 140, 573–582 (2014). https://doi.org/10.1007/s00432-014-1594-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-014-1594-6

Keywords

Search

Navigation